- Home
- APA vs ARWR Comparison
APA vs ARWR Comparison
Compare APA & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | APA | ARWR |
|---|---|---|
| Founded | 1954 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 12.4B |
| IPO Year | 2021 | 2009 |
Fundamental Metrics
Financial Performance| Metric | APA | ARWR |
|---|---|---|
| Price | $42.38 | $88.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 23 | 10 |
| Target Price | $31.96 | ★ $83.40 |
| AVG Volume (30 Days) | ★ 5.8M | 1.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | 75.77 | ★ 99.80 |
| EPS | ★ 3.37 | N/A |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $3.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.64 | $21.61 |
| 52 Week High | $45.66 | $95.49 |
Technical Indicators
Market Signals| Indicator | APA | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 61.50 | 55.76 |
| Support Level | $35.11 | $82.70 |
| Resistance Level | $45.36 | $90.97 |
| Average True Range (ATR) | 1.40 | 2.63 |
| MACD | -0.02 | -0.22 |
| Stochastic Oscillator | 60.96 | 65.47 |
Price Performance
Historical ComparisonAbout APA APA Corporation
APA Corp is an independent exploration and production company. It develops and produces crude oil, natural gas, and natural gas liquids. The company's business has oil and gas operations in four segments: Egypt, the North Sea, Suriname, and the U.S. The company generates the majority of its revenue from the U.S. reporting segment. The company also has exploration interests in Uruguay, Alaska, and other international locations.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.